BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 7853176)

  • 1. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1995 Feb; 272(2):628-38. PubMed ID: 7853176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1992 Jun; 261(3):985-93. PubMed ID: 1376362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    Eissenberg T; Greenwald MK; Johnson RE; Liebson IA; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1996 Feb; 276(2):449-59. PubMed ID: 8632309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
    Walsh SL; Preston KL; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute effects of pentazocine, naloxone and morphine in opioid-dependent volunteers.
    Lamas X; Farre M; Cami J
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1485-92. PubMed ID: 8138958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.
    Bickel WK; Stitzer ML; Bigelow GE; Liebson IA; Jasinski DR; Johnson RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):47-53. PubMed ID: 2459370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients.
    Lintzeris N; Mitchell TB; Bond AJ; Nestor L; Strang J
    Drug Alcohol Depend; 2007 Dec; 91(2-3):187-94. PubMed ID: 17624687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans.
    Schuh KJ; Walsh SL; Bigelow GE; Preston KL; Stitzer ML
    J Pharmacol Exp Ther; 1996 Aug; 278(2):836-46. PubMed ID: 8768738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
    Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
    Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine.
    Strain EC; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2002 Jan; 159(2):161-6. PubMed ID: 11862344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.
    Preston KL; Bigelow GE; Bickel W; Liebson IA
    J Pharmacol Exp Ther; 1987 Dec; 243(3):1002-9. PubMed ID: 2447262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of buprenorphine in buprenorphine-maintained volunteers.
    Strain EC; Walsh SL; Preston KL; Liebson IA; Bigelow GE
    Psychopharmacology (Berl); 1997 Feb; 129(4):329-38. PubMed ID: 9085402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.
    Foltin RW; Fischman MW
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1153-64. PubMed ID: 8819498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of buprenorphine and methadone effects on opiate self-administration in primates.
    Mello NK; Bree MP; Mendelson JH
    J Pharmacol Exp Ther; 1983 May; 225(2):378-86. PubMed ID: 6188822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.